As of 26 May 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Japanese encephalitis vaccine for the prevention of Japanese encephalitis among children 9 to 59 months old in high risk areas as defined in the DOH Omnibus Health Guidelines (OHG) for Children under 10 years (2023), continue reading : HTA Council Preliminary Recommendation on Japanese Encephalitis Vaccine (JEV)
HTA Council Preliminary Recommendation on Human Immunodeficiency Virus (HIV) Self Test Kit, HIV/Syphilis Duo Test, In Vitro Quantitative HIV Nucleic Acid Test (HIV-NAT 1), and Silver Diamine Fluoride 38% Clear Topical Solution
As of 26 May 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of the following health technologies for possible government financing: These health technologies were reviewed against clinical practice guidelines (CPGs) [local and approved by the DOH, such as the DOH Omnibus Health Guidelines (OHG); and/or international, but locally continue reading : HTA Council Preliminary Recommendation on Human Immunodeficiency Virus (HIV) Self Test Kit, HIV/Syphilis Duo Test, In Vitro Quantitative HIV Nucleic Acid Test (HIV-NAT 1), and Silver Diamine Fluoride 38% Clear Topical Solution
HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b
As of 05 March 2025, the Health Technology Assessment (HTA) Council makes public its preliminary recommendation on the non-inclusion in the PNF and thus the non-government financing of hexavalent vaccine, for stakeholder feedback/comments. Overall, the HTA Council recognizes that hexavalent vaccines will result in a simpler immunization schedule and thus, better compliance and easier implementation. continue reading : HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b
HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution
Update as of 25 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution ended on 22 November 2024 without valid appeals received, this continue reading : HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution
HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir
Update as of 06 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir ended on 05 November 2024 without appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to the Secretary of continue reading : HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir